Eli Lilly said on June 5, 2024 that Anat Ashkenazi resigned as executive vice president and chief financial officer to pursue another career opportunity outside the pharmaceutical industry.

1. 01

   Eli Lilly said on June 5, 2024 that Anat Ashkenazi resigned as executive vice president and chief financial officer to pursue another career opportunity outside the pharmaceutical industry.

2. 02

   The company said Gordon Brooks, 55, group vice president, controller and corporate strategy, will serve as interim chief financial officer starting July 15, 2024.

3. 03

   The company said Gordon Brooks has held several leadership roles across its finance organization over his 29-year career, including serving as senior vice president and chief procurement officer from February 2019 to March 2024.

4. 04

   The company said there are no arrangements or understandings between Gordon Brooks and any person under which he was selected as an officer, and no family relationship with any director or executive officer. It said Anat Ashkenazi will remain with the company through the end of July 2024 to help transition her responsibilities.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.